Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT03287063 | Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma | terminated | — | 6 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04406272 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | terminated | Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | terminated | Phase 1 | 5 | Columbia UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT00527410 | A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis(LMD) | terminated | Phase 1 | 9 | BiogenINDUSTRY | 1 | May 30, 2025 | clinicaltrials |
| NCT05297864 | PARP Inhibition for Gliomas (PI-4G or π4g)(OU-SCC-PI-4G) | terminated | Phase 2 | 15 | University of OklahomaOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | terminated | Phase 1 | 144 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT03593330 | Neurosurgical Transitional Care Programme(TCP) | terminated | N/A | 242 | Barts & The London NHS TrustOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04006119 | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 40 | Alaunos TherapeuticsINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | terminated | Phase 1 / Phase 2 | 57 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT02584647 | PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors(PLX3397) | terminated | Phase 1 / Phase 2 | 39 | Gulam ManjiOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors(STIR) | terminated | Phase 2 | 15 | Monica ThakarOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | terminated | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04469699 | Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma(NOA11) | terminated | Phase 2 | 30 | University Hospital MuensterOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04897880 | A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT(NORTH) | terminated | Phase 2 | 25 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 3 | Feb 24, 2025 | clinicaltrials |
| NCT05737212 | Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas | terminated | Phase 1 / Phase 2 | 7 | Dawonmedax Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT02722512 | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine | terminated | Phase 1 | 10 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT03016091 | A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma | terminated | Phase 2 | 18 | Rabin Medical CenterOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | terminated | Phase 1 | 134 | Jazz PharmaceuticalsINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04047602 | Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study(RADREMI) | terminated | N/A | 18 | Indiana UniversityOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05324501 | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma(MAGIC-G1) | terminated | Phase 1 | 4 | Biodexa PharmaceuticalsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT01814813 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | terminated | Phase 2 | 90 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03717142 | Feasibility of the LUM Imaging System for Detection of Cancer to the Brain | terminated | N/A | 4 | Lumicell, Inc.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04397679 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma | terminated | Phase 1 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT02525692 | Oral ONC201 in Adult Recurrent Glioblastoma | terminated | Phase 2 | 84 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)(KONQUER) | terminated | Phase 1 | 10 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 74 | Karyopharm Therapeutics IncINDUSTRY | 2 | Dec 16, 2024 | clinicaltrials |
| NCT04128774 | Function and Composition of Regulatory B Cells in Participants With Glioblastoma(GBMdexaB) | terminated | — | 5 | Amsterdam UMC, location VUmcOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT02372409 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | terminated | Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03973918 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG(BRAF) | terminated | Phase 2 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04952571 | Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM) | terminated | Phase 2 | 3 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03363659 | Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme | terminated | Phase 2 | 15 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT06625359 | High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma | terminated | Phase 2 | 17 | Seoul National University HospitalOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT01246869 | Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water | terminated | Phase 1 | 2 | University of UtahOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04753658 | Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | terminated | — | 15 | PfizerINDUSTRY | 6 | Sep 23, 2024 | clinicaltrials |
| NCT00555399 | Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03539731 | [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers | terminated | Phase 1 | 27 | Guido A. Davidzon, MD, SMOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | terminated | Phase 1 / Phase 2 | 8 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | terminated | Phase 1 / Phase 2 | 14 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02630043 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | terminated | Phase 1 | 5 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04324840 | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 184 | CelgeneINDUSTRY | 7 | Jul 26, 2024 | clinicaltrials |
| NCT05370508 | A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM | terminated | Phase 1 / Phase 2 | 8 | SonALAsense, Inc.INDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04047303 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma | terminated | Phase 1 | 20 | CelgeneINDUSTRY | 2 | Jul 5, 2024 | clinicaltrials |
| NCT03250299 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 26 | Basilea PharmaceuticaINDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT04221061 | 18F-FluorThanatrace (PET/CT) in Glioblastoma | terminated | Early Phase 1 | 3 | University of PennsylvaniaOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT02924038 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | terminated | Phase 1 | 14 | Nicholas ButowskiOTHER | 1 | Jun 14, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 17, 2025source: clinicaltrials